Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Lacosamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 410Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Indoco Remedies Gets USFDA Nod To Sell Generic Epilepsy Medicine
    Indoco Remedies Gets USFDA Nod To Sell Generic Epilepsy Medicine

    30 Jan 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indoco-remedies-gets-usfda-nod-to-sell-generic-epilepsy-medicine/articleshow/127796239.cms

    ECONOMICTIMES
    30 Jan 2026
    Share Share
    Anthea Pharma’s Generics Lacosamide Receives Approval in US
    Anthea Pharma’s Generics Lacosamide Receives Approval in US

    21 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220268

    FDA
    21 Jan 2026
    Share Share
    Akums Reaffirms Lacosamide's Potential For Epilepsy Treatment
    Akums Reaffirms Lacosamide's Potential For Epilepsy Treatment

    22 Sep 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/akums-reaffirms-lacosamides-potential-for-epilepsy-treatment/

    EXPRESSPHARMA
    22 Sep 2025
    Share Share
    Ajenat’s Generics Lacosamide Receives Approval in US
    Ajenat’s Generics Lacosamide Receives Approval in US

    26 Jun 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219699

    FDA
    26 Jun 2025
    Share Share
    Enforcement Report - Week of June 11, 2025
    Enforcement Report - Week of June 11, 2025

    11 Jun 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-11-2025-53935.pdf

    FDA
    11 Jun 2025
    Share Share
    Enforcement Report - Week of April 16, 2025
    Enforcement Report - Week of April 16, 2025

    16 Apr 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-16-2025-39741.pdf

    FDA
    16 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.